Showing 1011-1020 of 20381 results for "".
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
https://reachmd.com/programs/project-oncology/preventing-mgussmm-progression-to-multiple-myeloma-with-dietary-interventions/30046/A recent study found that a high-fiber, plant-based diet can delay progression from MGUS and SMM to multiple myeloma. Here are the best foods for patients.Assessing and Interpreting pCR in Perioperative NSCLC
https://reachmd.com/programs/project-oncology/perioperative-nsclc-pcr-assessment/49112/Pathologic complete response (pCR) has emerged as a key surrogate endpoint in perioperative non-small cell lung cancer (NSCLC), offering valuable insight into treatment efficacy and long-term outcomes. Joining Dr. Steve Jackson to discuss how pCR is defined and assessed following neoadjuvant therapySubcutaneous Isatuximab Matches IV in Multiple Myeloma: Insights from IRAKLIA
https://reachmd.com/programs/project-oncology/subcutaneous-isatuximab-matches-iv-in-multiple-myeloma-insights-from-iraklia/36403/The phase 3 IRAKLIA trial evaluated the subcutaneous delivery of isatuximab via an on-body injector plus pomalidomide and dexamethasone versus the standard IV regimen in patients with relapsed/refractory multiple myeloma. Results showed comparable overall response rates, steady-state trough concentrAdvances in Osteoporosis Treatment: Exploring Drug and Non-Drug Interventions
https://reachmd.com/programs/frontlines-osteoporosis/advances-in-osteoporosis-treatment-exploring-drug-and-non-drug-interventions/32344/Treatment for osteoporosis spans a variety of drug and non-drug interventions, from proper nutrition and exercise to anabolic and antiresorptive agents. In addition to understanding the importance of these therapies, it's crucial to recognize the patient's individual risks and needs and personalizeImproving CKD Patient Outcomes with SGLT2 Inhibitors
https://reachmd.com/programs/clinicians-roundtable/improving-ckd-patient-outcomes-with-sglt2-inhibitors/17943/How are SGLT2 inhibitors helping patients with CKD? Tune in.Potential for Early Intervention in 1L HR+/HER2- Advanced Breast Cancer
https://reachmd.com/programs/medical-industry-feature/potential-for-early-intervention-in-1l-hrher2-advanced-breast-cancer/39209/To help patients with HR+/HER2- advanced breast cancer have the best chance of extending the benefit of first-line aromatase inhibitor plus CDK4/6 inhibitor regimens, it may be critical to detect emerging endocrine resistance as early as possible.1-3 As exposure to aromatase inhibitors increases, EJAMA: Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies
https://reachmd.com/programs/Audioabstracts/jama-noninvasive-prenatal-testing-and-incidental-detection-occult-maternal-malignancies/7628/Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies Diana W. Bianchi, MD; Darya Chudova, PhD; Amy J. Sehnert, MD; Sucheta Bhatt, MD; Kathryn Murray, MS; Tracy L. Prosen, MD; Judy E. Garber, MD; Louise Wilkins-Haug, MD, PhD; Neeta L. Vora, MD; Stephen Warsof, MD; JamA Look at Immunizations Through Time
https://reachmd.com/programs/covid-19-frontlines/a-look-at-immunizations-through-time/11580/Immunization techniques have been evolving since the 1100s. Could the techniques of the past help us in our current hunt for a COVID-19 vaccine?Women In Aesthetics: Mary Gardner, DelNova, Inc
https://reachmd.com/topics/skincare/women-in-aesthetics-mary-gardner-delnova-inc/35165/Innovations in Less-Invasive Epilepsy Surgery
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/innovations-in-less-invasive-epilepsy-surgery/39963/Recent developments in epilepsy surgery underscore a growing trend toward reduced invasiveness and expanded clinical indications.